Universität zu Köln

Grimminger, Peter P., Brabender, Jan, Warnecke-Eberz, Ute, Narumiya, Kosuke, Wandhoefer, Christoph, Drebber, Uta, Bollschweiler, Elfriede, Hoelscher, Arnulf H., Metzger, Ralf and Vallboehmer, Daniel (2010). XRCC1 Gene Polymorphism for Prediction of Response and Prognosis in the Multimodality Therapy of Patients with Locally Advanced Rectal Cancer. J. Surg. Res., 164 (1). S. E61 - 6. SAN DIEGO: ACADEMIC PRESS INC ELSEVIER SCIENCE. ISSN 1095-8673

Full text not available from this repository.

Abstract

Background. Neoadjuvant treatment strategies have been developed to improve survival of patients with locally advanced rectal cancer. Since mainly patients with major histopathologic response benefit from this therapy, predictive markers are needed. The gene polymorphism of the X-ray-repair-cross complementing (XRCC1-) gene (rs25487) was analyzed to predict response to neoadjuvant radiochemotherapy and prognosis in patients with locally advanced rectal cancer. Patients and Methods. 81 patients (51 male; 30 female; median age 59 years) with locally advanced rectal cancer were included in this study. All patients received a neoadjuvant radiochemotherapy (50.4 Gy, 5-FU) followed by surgical therapy. Histomorphologic regression was defined as major response when resected specimens contained less than 10% viable tumor cells (n = 28) and minor response when more than 10% viable tumor cells (n = 53) were detected in the surgical specimen. Genomic DNA was extracted from paraffin-embedded tissues of all study patients. Allelic discrimination was performed by real-time polymerase chain reaction. Two allele-specific TaqMan probes in competition were used for amplification of the XRCC1 gene. Allelic genotyping was correlated with therapy response and prognosis. Results. Single-nucleotide polymorphism XRCC1 A399G (rs25487) was predictive for therapy response (P = 0.039). Within the AG genotype group, 17 (53%) patients showed a minor response and 15 (47%) patients a major response. In contrast, 39 (78%) of the patients with homogeneous AA or GG genotype were minor responders and only 11 (22%) major responders. No prognostic value was revealed for the XRCC1 A399G (rs25487) gene polymorphism in the multimodality therapy. Conclusion. Our data supports the role of XRCC1 as a predictive marker for therapy response in the multimodality therapy of patients with locally advanced rectal cancer. Single-nucleotide polymorphism XRCC1 A399G (rs25487) could be applied to individualize treatment strategies. (C) 2010 Elsevier Inc. All rights reserved.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Grimminger, Peter P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Brabender, Jan UNSPECIFIED UNSPECIFIED UNSPECIFIED Warnecke-Eberz, Ute UNSPECIFIED UNSPECIFIED UNSPECIFIED Narumiya, Kosuke UNSPECIFIED UNSPECIFIED UNSPECIFIED Wandhoefer, Christoph UNSPECIFIED UNSPECIFIED UNSPECIFIED Drebber, Uta UNSPECIFIED UNSPECIFIED UNSPECIFIED Bollschweiler, Elfriede UNSPECIFIED UNSPECIFIED UNSPECIFIED Hoelscher, Arnulf H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Metzger, Ralf UNSPECIFIED UNSPECIFIED UNSPECIFIED Vallboehmer, Daniel UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-493665
DOI:	10.1016/j.jss.2010.08.002
Journal or Publication Title:	J. Surg. Res.
Volume:	164
Number:	1
Page Range:	S. E61 - 6
Date:	2010
Publisher:	ACADEMIC PRESS INC ELSEVIER SCIENCE
Place of Publication:	SAN DIEGO
ISSN:	1095-8673
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; DNA-REPAIR GENES; PREOPERATIVE CHEMORADIATION; THYMIDYLATE SYNTHASE; TUMOR-REGRESSION; NEOADJUVANT RADIOCHEMOTHERAPY; POSTOPERATIVE CHEMORADIOTHERAPY; ESOPHAGEAL CANCER; SURVIVAL Multiple languages Surgery Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/49366